A vial labelled “AstraZeneca COVID-19 Vaccine” is seen in this illustration taken January 16, 2022.
13:09 JST, May 8, 2024
AstraZeneca AZN.Lsaid on Tuesday it had initiatedthe worldwide withdrawal ofits COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic.
The company also said it would proceed to withdraw the vaccine Vaxzevria’s marketing authorizations within Europe.
“As multiple, variant COVID-19 vaccines have since been developed there is a surplus of available updated vaccines,” the company said, adding that this had led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied.
According to media reports, the Anglo-Swedish drugmaker has previously admitted in court documents that the vaccine causes side-effects such as blood clots and low blood platelet counts.
The firm’s application to withdraw the vaccine was made on March 5 and came into effect on May 7, according to the Telegraph, which first reported the development.
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
"News Services" POPULAR ARTICLE
-
American Playwright Jeremy O. Harris Arrested in Japan on Alleged Drug Smuggling
-
Taiwan President Shows Support for Japan in China Dispute with Sushi Lunch
-
Japan’s Nikkei Stock Average as JGB Yields, Yen Rise on Rate-Hike Bets
-
Japan’s Nikkei Stock Average Licks Wounds after Selloff Sparked by BOJ Hike Bets (UPDATE 1)
-
Japanese Bond Yields Zoom, Stocks Slide as Rate Hike Looms
JN ACCESS RANKING
-
Keidanren Chairman Yoshinobu Tsutsui Visits Kashiwazaki-Kariwa Nuclear Power Plant; Inspects New Emergency Safety System
-
Imports of Rare Earths from China Facing Delays, May Be Caused by Deterioration of Japan-China Relations
-
Japan Exports Rise in October as Slump in U.S. Sales Eases
-
Govt Aims to Expand NISA Program Lineup, Abolish Age Restriction
-
Blanket Eel Trade Restrictions Rejected

